| Title: | Determinants and clinical significance of cerebral small vessel disease |
| Lead Institution: | University of Bordeaux |
| Principal investigator: |
Application 94113
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Stroke and dementia are the most common age-related causes of death and disability, representing a huge burden for society. Cerebral small vessel disease (cSVD) is a group of diseases affecting the small vessels that supply blood to the brain. The brain abnormalities that characterize cSVD, and that are due to damage to these small vessels, can be seen on brain images, particularly Magnetic Resonance Imaging (MRI). With increasing age, cSVD becomes very common and is often "covert" in older adults, meaning that abnormalities are detectable on brain MRI but not associated with clinical stroke. Knowing that covert cSVD is a strong predictor of future stroke, cognitive decline and dementia in older adults, better detection and management of covert cSVD could have a major impact on preventing disability and costs associated with these neurological diseases. The current incomplete understanding of the biological mechanisms leading to cSVD is one of the reasons for the current lack of clinically useful "biological markers" and of specific treatments for this disease. Therefore, efforts to improve our understanding of the biological mechanisms causing cSVD and to identify both early disease markers and new drug targets for cSVD are of great importance. We aim to use the UK Biobank data to: (1) develop imaging methods allowing to accurately quantify cSVD imaging abnormalities on brain MRI; (2) explore cardiovascular and retinal features of cSVD using cardiovascular and retinal imaging (leveraging the similarities between retinal and brain small vessels), and identify shared biological pathways; (3) discover novel genetic risk factors for cSVD as well as circulating blood molecular biomarkers such as proteins or metabolites; (4) improve risk prediction of stroke and dementia in persons with covert cSVD, based on imaging and circulating biomarkers, using novel statistical methods. In terms of public health impact, this project will facilitate early diagnosis of cSVD to improve detection of at-risk subjects and prevent the occurrence of stroke and dementia. It will provide a better understanding of disease mechanisms and accelerate drug target discovery. In the long run, our research will contribute to the development of personalized preventive and therapeutic strategies for cSVD and its complications.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 9219 | Early detection of white matter hyperintensities using SHIVA-WMH detector | Ami Tsuchida (+5) | 2023 | Human Brain Mapping |
Enabling scientific discoveries that improve human health